The influence of physostigmine on visual-vestibular interaction in hereditary ataxias

CC TIJSSEN,† LJ ENDTZ,* C GOOR†

From the Departments of Neurology* and Neurophysiology,† Municipal Hospital Leyenburg, The Hague, The Netherlands

SUMMARY Visual suppression of caloric nystagmus was studied in five patients with hereditary ataxia before and after administration of physostigmine. All patients had an initial abnormal ocular fixation index that improved after physostigmine was given. The data indicate that there is a partly reversible disturbance of visual-vestibular interaction in patients with hereditary ataxia, caused by an impairment of a central cholinergic mechanism.

The hereditary ataxias constitute a number of degenerative cerebellar diseases having ataxia as their common feature. The pathophysiological basis underlying this group of disorders is unknown. Hereditary factors play an important role in their aetiology but sporadic cases also occur.¹ Recent studies have indicated a possible biochemical deficit. Primary or secondary abnormalities of pyruvate metabolism have been identified in up to 50% of unselected series of patients with hereditary ataxias,² ³ and in patients with Friedreich's ataxia a lowered activity of pyruvate oxidation caused by a defect at the level of the third component of the pyruvate dehydrogenase complex, that is the lipoamide dehydrogenase, has been demonstrated.⁴ ⁵ This disturbance of the pyruvate metabolism leads to impaired production of acetyl-coenzyme A and subsequently to impaired synthesis of the neurotransmitter acetylcholine.² ⁶ Acetylcholine synthesis seems exquisitely sensitive to impaired pyruvate oxidation.³ Clinical studies have suggested that low doses of physostigmine, a centrally active cholinesterase inhibitor, improve signs of ataxia in patients with hereditary ataxias.⁷ ⁸ ⁹ Objective criteria to evaluate the influence of this drug are however lacking.

A number of ocular abnormalities occur in hereditary ataxias including nystagmus (especially gaze-evoked, rebound and downbeat nystagmus), impaired smooth pursuit, saccadic dysmetria and defective visual suppression of vestibular nystagmus.¹⁰ ¹² The ability to suppress the vestibulo-ocular reflex (VOR) by fixation is a valuable indication of cerebellar pathology.¹² ¹³ ¹⁴ There is evidence that the vestibulo-cerebellum, especially the flocculus, is an important site for this visual-vestibular interaction that facilitates adaptive changes in the VOR.¹⁶ ²¹

In this study we investigated the influence of the drug physostigmine on the visual suppression of caloric-induced vestibular nystagmus in five patients with hereditary ataxia.

Material and methods

Five patients with hereditary ataxia were studied, whose relevant data are summarised in the table. The patients used no drugs at the time of investigation. Each subject was examined with electro-nystagmography (ENG) equipment using a time constant of 5 seconds and a filter of 15 Hz (3 dB). Horizontal eye movements were recorded with surface electrodes placed near the inner and outer canthus of both eyes. A voluntary eye movement over 20° was used for calibration of the angular velocity of the slow phase of the nystagmus. Caloric stimulation was applied by irrigating both ears with 50 ml of water at 30°C during 20 seconds with eyes closed. If no good response was obtained water at 15°C was also applied. With this procedure a maximum slow phase eye velocity occurs at about 45 seconds after the onset of irrigation and maintains for about 30 seconds.²⁹ The visual suppression test was carried out during this maximum intensity of caloric nystagmus at 55 seconds after the onset of irrigation. The patients were asked to open their eyes and fix their gaze upon a red spot light at a distance of 1½ metre for 15 seconds. Nystagmus frequency, amplitude and slow phase velocity, which was averaged over 10 wave forms, were measured before and after eye opening. The maximum response during visual
fixation was selected. Visual suppression was quantified according to the ocular fixation index. This index is obtained by the slow phase velocity (SPV) of the nystagmus during ocular fixation (EO) divided by the SPV of the nystagmus with eyes closed (EC) according to the formula:

\[
\text{Ocular fixation index} = \frac{\text{SPV.EO}}{\text{SPV.EC}}
\]

Informed consent was obtained from the patients, and subsequently 1 mg physostigmine was given intravenously. Fifteen minutes after the injection the test procedures were repeated with the same water temperature. To prevent any adaptation at least 30 minutes were taken between the caloric stimulations without and with physostigmine.

**Results**

With their eyes closed the caloric responses were bilaterally reduced in two patients, showing a maximum slow phase velocity of the nystagmus of 10° and 12°/s. The other three patients had normal slow phase velocities for post-caloric nystagmus with values ranging from 24 to 35°/s. The ocular fixation index of the patients before and after administration of physostigmine are given in the table. In humans the ocular fixation index has an upper normal limit of approximately 0-5. All five patients had an abnormal ocular fixation index, ranging from 0-56 to 2-00. After intravenous physostigmine the ocular fixation index of the patients improved significantly (p < 0-01 on Student's t test), patient 5 was even showing a completely normal ocular fixation index of 0, which means a visual suppression of 100% (fig 1, A, B). Caloric nystagmus and visual suppression before and after treatment of patient 3 are shown in fig 2 (A, B). It was noted that the greatest improvement occurred in the patients with shorter duration of their symptoms (patients 1, 2 and 5). Intravenous physostigmine produced some excessive sweating in three, and abdominal discomfort in two of the five patients. These complaints disappeared within an hour and no special measures were needed.

**Discussion**

Some clinical studies have dealt with the beneficial effect of physostigmine in patients with hereditary ataxias. Low doses of this drug improved signs of ataxia in both short-term and long-term management of these patients. The improvement was mainly determined by ataxia scores and videotape recording. We studied an objective parameter, that is the visual suppression of caloric nystagmus to evaluate the influence of physostigmine in five patients with hereditary ataxias. All five patients had an initial abnormal ocular fixation index that improved significantly after intravenous physostigmine (table); one patient even had a normal ocular fixation index after treatment. Two patients showed reduced responses after caloric stimulation with decreased slow phase velocity of the nystagmus. Reduced vestibulo-ocular responses to caloric stimulation have also been reported in previous cases of hereditary ataxias, especially in patients with Friedreich's ataxia. Three patients had an ocular fixation index above 1-0 which means that the nystagmus was greater with eyes open than with eyes closed. This phenomenon is called paradoxical response and has been reported in spinocerebellar

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Clinical features</th>
<th>Duration of symptoms (y)</th>
<th>Family history</th>
<th>CT scan</th>
<th>OFI*</th>
<th>OFI†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>60</td>
<td>ataxia, dysarthria, hyperreflexia, heterochromia iris ataxia, nystagmus, hyperreflexia Babinski sign ataxia, dysarthria</td>
<td>2</td>
<td>–</td>
<td>atrophy of pons and cerebellum</td>
<td>1-09</td>
<td>0-68</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>66</td>
<td></td>
<td>10</td>
<td>+</td>
<td>atrophy of cerebellum</td>
<td>2-00</td>
<td>1-52</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>50</td>
<td></td>
<td>30</td>
<td>+</td>
<td>atrophy of pons and cerebellum</td>
<td>0-76</td>
<td>0-61</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>70</td>
<td></td>
<td>23</td>
<td>–</td>
<td>atrophy of pons and cerebellum</td>
<td>1-14</td>
<td>0-90</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>21</td>
<td></td>
<td>2</td>
<td>+</td>
<td>atrophy of pons and cerebellum</td>
<td>0-56</td>
<td>0</td>
</tr>
</tbody>
</table>

OFI* = ocular fixation index before physostigmine
OFI† = ocular fixation index after physostigmine
The influence of physostigmine on visual-vestibular interaction in hereditary ataxias

disease, posterior fossa lesions, brainstem lesions, altered states of consciousness and in brain damage after head injury. The underlying mechanism is not certain.

It is known that the visual suppression of vestibular nystagmus is often impaired in patients with cerebellar disease, including hereditary ataxias. From experimental studies in animals it appears that this visual-vestibular interaction is mediated by the vestibulocerebellum, especially the cerebellar flocculus. The vestibulocerebellum (flocculus, nodulus, ventral uvula and ventral paraflocculus) receives input from the VOR through mossy fibre projections from the ipsilateral vestibular nerve and the vestibular nuclei. The Purkinje cells of the flocculus in turn project direct inhibitory axons to the ipsilateral vestibular nuclei, resulting in control over the VOR. Whether the climbing fibre pathway or the mossy fibre pathway is responsible for adjustment of the VOR has not been clearly established yet, but especially the mossy fibre pathway seems to be involved. Finally the cortical smooth pursuit system also plays an important role in the visual suppression of the VOR.

Histochemical studies have shown high cholinergic activity in the inferior olive, especially in the dorsal cap, the brainstem reticular formation, the lateral reticular nucleus in particular, and the

Fig 1 Caloric-induced vestibular nystagmus and visual suppression of case 5 before (A) and after (B) administration of physostigmine.

Fig 2 Caloric-induced vestibular nystagmus and visual suppression of case 3 before (a) and after (b) administration of physostigmine. This patient also shows the phenomenon of saccadic (flutter) dysmetria.
cerebral cortex.\textsuperscript{38-40} There is also evidence that the mossy fibre projections to the vestibulocerebellum have a cholinergic input.\textsuperscript{41} A reduced synthesis of acetylcholine, caused by a defect in the pyruvate metabolism, at any of these sites may result in a disturbance of visual-vestibular interaction and could account for the improvement of the ocular fixation indexes on physostigmine that we have seen in our patients. The results demonstrate that the disturbance of visual-vestibular interaction represented by the abnormal ocular fixation index is partly reversible. The improvement of the ocular fixation index was better in patients with shorter duration of symptoms, suggesting that irreversible processes appear in the course of time.

In conclusion, our study demonstrates that the visual suppression of vestibular nystagmus is disturbed in patients with hereditary ataxias. The impairment of visual-vestibular interaction is at least partly reversible and improves on intravenous physostigmine suggesting an acetylcholinergic disturbance. Further studies are required to investigate whether there is any relationship between the degree of improvement of the ocular fixation index and the beneficial effect of this drug on clinical symptoms in these patients.

The authors thank Dr TCAM van Woer Kum for his helpful criticism and Mrs Joke van der Veeken for secretarial assistance.

References

26. Korres S. Electronystagmographic criteria in neuro-
The influence of physostigmine on visual-vestibular interaction in hereditary ataxias


The influence of physostigmine on visual-vestibular interaction in hereditary ataxias.
C C Tijssen, L J Endtz and C Goor

*J Neurol Neurosurg Psychiatry* 1985 48: 977-981
doi: 10.1136/jnnp.48.10.977

Updated information and services can be found at:
http://jnnp.bmj.com/content/48/10/977

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/